The document describes an FDA-approved, CE-marked device called the EndoPAT 2000 that non-invasively measures endothelial function to detect early signs of heart disease. The device uses fingertip probes to measure endothelial function through a 15-minute test that can be administered in a doctor's office. Benefits include increasing office revenue, improving patient care through early detection of risk factors, and monitoring treatment effectiveness. The device costs $250,000 but can provide a profit within 4 months for practices performing a modest number of tests per day.

1. PRESENTED BY MEDVICA INT’L“The electric thimble that detects signs of heart disease”Ron Lazzarini – 970.227.1314 – rlazzarini@medvica.com

2. What is it?FDA approved, CE-marked, and validated by nearly 100 papers in peer-reviewed journalsThis device non-invasively measures endothelial functionEndothelial dysfunction is defined as either decreased bioavailability of nitric oxide (which is integral to endothelial health), or as an impairment of endothelium-dependent vasodilationSystemic manifestations of endothelial dysfunction include: stroke/TIA’s, sudden death from myocardial infarction, renal failure, sleep apnea, erectile dysfunction, metabolic syndrome, claudication, and gangrene.

4. How does it work?Fingertip probes measure endothelial functionDevice software automatically records and analyzes test results15 minute test can be given by a tech while the patient waits for the doctor

5. Test example

6. What are the benefits?CPT coded (93923) for simple billing and minimal conflict with insurance companies

7. Increases office revenue while simultaneously increasing the patients’ quality of care and quality of life

8. Provides incremental data to better predict and treat patients at risk for CVD, patients who would otherwise go undetected.

9. More effectively monitor treatment for better patient outcomes.

10. Measures earliest signs of atherosclerosis, while it is still reversible

11. Monitors effectiveness of patients being treated for cardiac disease

12. Who is it for?Patients who have one or more cardiac risk factorsPatients on medications – looking for response and non respondersFamily members of patients diagnosed with CAD

13. What’s the point?Improved quality of patient care.Better patient monitoring means improved cardiac health and fewer cardiac events.Reduce healthcare costs. $28.6B per year is spent on treating patients with congestive heart failure. EndoPAT detects cardiac risk while it is still reversible.Increase revenue for doctors. Private insurers reimburse up to $500 per test, adding to the bottom-line of the doctor’s office.

14. How much does it cost?IRS Section 179 allows businesses to immediately expense the first $250,000 of capital equipment purchased each year against current year net income.